<DOC>
	<DOCNO>NCT02600429</DOCNO>
	<brief_summary>The objective study assess safety efficacy RGN-259 Ophthalmic Solution compare placebo treatment NK .</brief_summary>
	<brief_title>Assessment Safety Efficacy Study RGN-259 Ophthalmic Solutions Neurotrophic Keratopathy : SEER-1</brief_title>
	<detailed_description>Neurotrophic keratopathy ( NK ) degenerative corneal disease occur result partial total impairment trigeminal innervation . The resulting loss corneal sensitivity ( anesthesia ) lead reduction lacrimation decline status , metabolism , mitosis corneal epithelial cell . Previous study ( physician-sponsored study ) use treat nine patient NK , six discrete geographic , non-healing lesion , three punctate lesion study result report .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Be male female race , least 18 year age Have provide verbal write informed consent . Be able willing follow instruction , include participation study assessments visit ; Have stage 2 3 neurotrophic keratopathy least one eye If female childbearing potential , negative urine pregnancy test Visit 1 agree use adequate method birth control throughout study period . Have clinically significant slit lamp finding Visit 1 opinion investigator may interfere study parameter ; Have significant blepharitis , meibomian gland dysfunction ( MGD ) , lid margin inflammation active ocular allergy require treatment Have lid function abnormality ( ex . Lagophthalmos ) , opinion investigator , primary cause persistent epithelial defect ; Be diagnose ongoing ocular infection ( bacterial , viral fungal ) active inflammation ( e.g . follicular conjunctivitis ) relate NK Anticipate use fluoroquinolonecontaining antibiotic eye drop study ; Have use contact lens ( exclude therapeutic contact lens ) within 14 day prior Visit 1 anticipates use contact lens study period ; Have uncontrolled systemic disease opinion investigator may interfere study parameter ; Anticipate change immunosuppressive therapy course study ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neurotrophic Keratopathy</keyword>
	<keyword>NK</keyword>
</DOC>